Skip to main content
CRISPR Therapeutics AG logo

CRISPR Therapeutics AG — Investor Relations & Filings

Ticker · CRSP ISIN · CH0334081137 LEI · 506700O6IRRIQLT3W370 US Manufacturing
Open in API
Filings indexed 821 across all filing types
Latest filing 2018-09-05 Director's Dealing
Country CH Switzerland
Listing US CRSP

About CRISPR Therapeutics AG

https://crisprtx.com/

CRISPR Therapeutics AG is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. The company leverages this technology to make precise, directed changes to genomic DNA. As a pioneer in the field, CRISPR Therapeutics has established a diverse portfolio of therapeutic programs across several disease areas, including hemoglobinopathies (such as sickle cell disease and beta-thalassemia), immuno-oncology, regenerative medicine, and cardiovascular disease. The company was one of the first to advance a CRISPR-based therapy into clinical trials and receive regulatory approval, aiming to create potentially curative treatments for patients.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2018-09-05 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 31, 2018, by CRISPR Therapeutics AG. It announces the entry into a material definitive agreement with Jefferies LLC for an Open Market Sale Agreement to offer and sell common shares up to $125 million. The document includes details about the agreement, the offering, and references to exhibits such as the agreement text and legal opinion. There are no financial statements or comprehensive financial data presented, nor is this a full annual or quarterly report. The content focuses on a capital raising transaction and related agreement, which fits the category of Capital/Financing Update. The document length is 5644 characters, sufficient to contain substantive information about the financing agreement rather than a brief announcement. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2018-08-31 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act of 1933. It relates to an offering of common shares by CRISPR Therapeutics AG, describing terms of the offering, risk factors, use of proceeds, dilution, dividend policy, and plan of distribution. The document is a detailed disclosure related to capital raising and securities issuance. It is not a financial report, earnings release, or management discussion. It is a capital markets document focused on financing activities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and content confirm it is a full prospectus supplement, not a brief announcement or regulatory filing.
2018-08-31 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 7, 2018, reporting the financial results for the second quarter ended June 30, 2018. It includes a press release as an exhibit announcing these results. The text explicitly states that the press release is furnished and not filed, and the document is short (3305 characters). The content is an announcement of financial results rather than the full financial report itself. According to the rules, initial announcements of quarterly financial results are classified as Earnings Release (ER).
2018-08-07 English
10-Q
Interim / Quarterly Report Q2 2018
2018-08-07 English
FORM 4 SUBMISSION
Director's Dealing
2018-08-03 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.